Sumary of Prior symptomatic COVID-19 enhances mRNA vaccine response:
- The coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), originally emerged in Wuhan, China in December 2019. Since then, SARS-CoV-2 has infected over 226 million and caused the deaths of over 4.6 million worldwide.
- The study findings suggest that one dose of a vaccine with high efficacy may be sufficient to protect the previously infected;
- Study: Determinants of Early Antibody Responses to COVID-19 mRNA Vaccines In Exposed and Naive Healthcare Workers.
- com Background The widespread rollout of COVID-19 vaccines significantly reduced hospitalizations and mortality in several developed countries.
- The first vaccines to receive emergency approval were the Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-95 1273) vaccines, both of which are based on messenger ribonucleic acid (mRNA) technology that encodes for the viral spike glycoprotein.
- Both mRNA vaccines have demonstrated vaccine efficacies of 94% or above after a two-dose regimen in Phase III clinical trials.
- Real-world effectiveness has also been shown to be high, though the efficacy has decreased against the currently dominant SARS-CoV-2 Delta variant of concern (VOC).
- Limited supplies of vaccines in many countries have led to a re-examination of immunization policies in terms of a delayed second dose or putting naïve individuals at a higher priority for vaccination as compared to those with a previous history of natural infection.